Nuevolution, GSK Sign Cross License | GenomeWeb

Nuevolution, GSK Sign Cross License

Jul 28, 2009

NEW YORK (GenomeWeb News) – Danish firm Nuevolution and drugmaker GlaxoSmithKline have inked a cross-licensing agreement covering DNA-tagging, synthesis, and small molecule compounds, Nuevolution said today.

Under the agreement, GSK will obtain a non-exclusive license for Nuevolution's technology, and Nuevolution will obtain a one-time license fee and a non-exclusive license under GSK's patents.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Blame the Follicles

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Missed a Few

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

This Week in Cell

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Yep, Couple of Concerns There

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.